Skip to Content

Alzheimer’s drug gets FDA panel’s backing, setting the stage for broader use


AP Health Writer

WASHINGTON (AP) — U.S. health advisers are backing the full approval of an Alzheimer’s drug that received preliminary approval last year. A panel of advisers to the Food and Drug Administration on Friday voted in favor of the infused medication from drugmakers Eisai and Biogen. The FDA granted accelerated approval in January based on early results suggesting the drug could modestly slow Alzheimer’s. Friday’s full-day meeting focused on more recent study results intended to show that the drug clearly benefits patients. A decision from FDA is expected by July 6. It will be significant because insurers have delayed paying for the drug until it has full approval.

Article Topic Follows: AP National

Jump to comments ↓

Author Profile Photo

Associated Press


KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content